VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas

Trial ID or NCT#

NCT01289210

Status

not recruiting iconNOT RECRUITING

Purpose

This study is to determine the safety and effectiveness of VTX-2337 (an investigational drug that stimulates the immune system) in combination with radiation therapy in treating patients with low-grade B-cell lymphoma. Patients will receive 2 low doses of radiotherapy, and 9 intratumoral injections of VTX-2337 over the course of 3 months.

Official Title

A Phase I/II Study of Intratumoral Injection of the Small Molecule TLR8 Agonist VTX-2337 in Combination With Local Radiation in Low-Grade B-cell Lymphomas

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Manali Patel
Manali Patel
Medical oncologist
Associate Professor of Medicine (Oncology)
Ronald Levy
Ronald Levy
Medical oncologist, Lymphoma specialist
Robert K. and Helen K. Summy Professor in the School of Medicine

Contact us to find out if this trial is right for you.

Contact

Lori Richards
6507258589

View on ClinicalTrials.gov